Обзорная статья

The Potential Revolution of Cancer Treatment with CRISPR Technology

Dimitrios StefanoudakisSchool of Medicine, National & Kapodistrian University of Athens, 15772 Athens, GreeceNikhita Kathuria‐PrakashDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USAAlexander W. SunDepartment of Internal Medicine, Columbia University, New York, NY 10027, USAMelissa L. AbelDivision of Hematology and Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USAClaire DrolenDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USACamille AshbaughDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USAShiliang ZhangDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USAGavin HuiDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USAYeganeh A. TabatabaeiDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USAYuliya ZektserDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USALidia LópezDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USAAllan J. PantuckDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USAAlexandra DrakakiDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA

2023en

ABI

Аннотация

Immuno-oncology (IO) and targeted therapies, such as small molecule inhibitors, have changed the landscape of cancer treatment and prognosis; however, durable responses have been difficult to achieve due to tumor heterogeneity, development of drug resistance, and adverse effects that limit dosing and prolonged drug use. To improve upon the current medicinal armamentarium, there is an urgent need for new ways to understand, reverse, and treat carcinogenesis. Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) 9 is a powerful and efficient tool for genome editing that has shown significant promise for developing new therapeutics. While CRISPR/Cas9 has been successfully used for pre-clinical cancer research, its use in the clinical setting is still in an early stage of development. The purpose of this review is to describe the CRISPR technology and to provide an overview of its current applications and future potential as cancer therapies.

Перевод пока недоступен

Идентификаторы

DOI: 10.3390/cancers15061813

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar